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Background: The effect of insufficient node sampling in patients with rectal cancer managed by neoadjuvant
chemoradiation followed by surgery has not been clearly determined. We evalulated the impact of insufficient
sampling or even abscence of lymph nodes in the specimen on survival in patients at high-risk (T3, T4 or node
positive) for rectal cancer.
Methods: We conducted a single institution, retrospective analysis of all patients who underwent surgical rectal
resection following neoadjuvant chemoradiation for treatment of mid to lower rectal cancer between 1997 and
2009. ypNX was defined as the absence of lymph nodes retrieved in the resected specimen.
Results: A total of 132 patients underwent resection for treatment of rectal cancer following neoadjuvant
chemoradiation. Ninety four patients (71.2%) were considered as having node-negative disease, including ypNx and
ypN0. In 38 patients (28.8%), the primary tumor was associated with regional lymph node metastases (ypNpos). The
mean number of retrieved nodes per specimen was 14.2, respectively. The five-year overall survival from initial
operation for the ypNx group was 100%, respectively. The estimated five-year overall survival for ypN0 and ypNpos
was 84.0% and 60.3%, respectively (P =0.001). No significant differences in overall survival were observed between
the ypNx and ypN0 group (P =0.302).
Conclusion: Absence of recovered LN in resected specimens after neoadjuvant chemoradiation was observed in
7.6% of specimens. Absence of LN should not be regarded as a risk factor for poor survival or as a sign of less
radical surgery.
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It is estimated that approximately 50 ~ 60% of rectal
cancers are considered to be locally advanced tumors
with clinical stage T3 or T4 or node positive disease,
characterized by poor prognosis due to increased inci-
dence of systemic and local recurrence and decreased
long-term survival [1]. The preferred strategy for man-
agement of locally advanced mid to distal rectal cancer
is multimodality treatment that includes radical surgery,
chemotherapy, and radiation therapy. Radical surgery* Correspondence: gsbaek@gilhospital.com; lwk@gilhospital.com
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reproduction in any medium, provided the orshould be performed according to established surgical
principles, which include en bloc resection of the tumor-
bearing rectum and the adjacent lymphovascular pedicle,
commonly referred to as total mesorectal excision [2].
The lymph node (LN) status remains one of the
independant prognostic factors in rectal cancer. Patients
without LN metastses have significantly better survival,
compared to node positive patients, in the abscence of
distant metastasis. However, a mininum number of LNs
retrieved from the resected specimen is prerequisite to
ensuring both adequate nodal sampling and surgical
radicality [3]. Several studies have demonstrated a sig-
nificant survival benefit of patients with node negative
disease with an increased number of recovered nodes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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down staging and rate of metastatic LN but also on the
overall number of retrieved nodes [7,8]. The number of
LNs assessed pathologically is a combination of the ag-
gressiveness of the surgeon in resecting widely around
the primary tumor and of the didicated pathologist in
searching the specimen for additional nodes. Inadequate
retrieval of LNs is considered unacceptable for patients
who have not undergone pretreatment and went
straight to surgery. However, the effect of this finding in
patients with rectal cancer managed by neoadjuvant
chemoradiation followed by surgery has not yet been
determined.
In an attempt to determine the impact of insufficient
sampling (i.e. ypN ≤ 12) or even abscence of lymph nodes
in the specimen (i.e. ypNx) on survival in these patients,
we evaluated a cohort of patients who enrolled in our
neoadjuvant chemoradiation protocol for patients with
high-risk (T3, T4 or node positive) rectal cancer.
Patients and methods
Eligibility
Between September 1997 and September 2009, 720 pa-
tients with rectal cancer underwent treatment at Gachon
Medical Center. The inclusion criteria for the study were
as follows: 1) lesion located no more than 10 cm from
the anal verge; 2) clinical TNM stage II and III (T2-T4,
or N positive and M0) on abdominopelvic computated
tomography; 3) patients with histologically proven rectal
carcinoma; 4) age ≥18 years; 5) patients who underwent
preoperative chemoradiation; 6) mid (anal verge 6 cm to
10 cm) and lower (anal verge 1 cm to 5 cm) rectal cancer
patients. Of the 720 patients screened for rectal resection,
132 patients fulfilled the inclusion criteria and were
included in this retrospective analysis.
Pretreatment staging
Initial staging included complete physical examination,
digital rectal examination, colonoscopy, serum CEA
(carcino-embryonic antigen) abdominal and pelvic spiral
CT scans, and endorectal ultrasonography or rectal mag-
netic resonance imaging in selected patient chest X-ray.
Treatment
All patients received two initial cycles of chemotherapy
followed by pelvic radiation therapy plus chemotherapy.
The concurrent chemotherapy was performed at the first
and fifth week of radiation with bolus intravenous 5-
fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for
five days per week. All patients received external beam
radiation therapy (median dose, 50.40 Gy; range 48.4 to
55.8 Gy), according the previously published techniques
[9,10]. Using 6 to 10 Mv photons, a 3- or 4-field tech-
nique was used.Surgery was attempted at 6–8 weeks after completion of
neoadjuvant chemoradiotherapy. All patients underwent
low anterior resection or abdominoperineal resection and
total mesorectal excision (TME) according to the surgical
technique described by Heald et al. [11] as well as high
ligation inferior mesenteric artery and en bloc resection of
any suspected adjacent organ invasion. Four cycles of
postoperative adjuvant chemotherapy with 5-fluorouracil
500 mg/m2 for five days was added.
Staging
Two pathologists performed meticulous dissection and
retrieval of mesorectal lymph nodes. A rigorous search
of the mesorectum was performed in order to identify as
many lymph nodes as possible. Each lymph node was
analyzed in its entirety in separate blocks. When fewer
than 12 lymph nodes were found, an additional 24-hour
surfixation in Bouin’s fluid was performed in order to fa-
cilitate recovery of residual lymph nodes. No clearing
technique was performed. Patients were staged according
to the American Joint Committee on Cancer recommen-
dations [12]. ypNX was defined as the absence of lymph
nodes recovered in the resected specimen.
Surveillance
Surveillance for recurrence following surgery was outlined
as follows: physical examination, serum CEA, chest X-ray,
and spiral abdominal CT scan were performed every six
months for three years, and annually thereafter.
Statistical methods
The primary endpoint of the study was overall survival.
Overall survival (OS) was estimated using the Kaplan-
Meier method. OS was measured from the date of diagno-
sis to the date of death or the last follow-up visit. Survival
rates were compared for statistical differences using
log-rank analysis. Chi squared and ANOVA were used
for categorical and numeral variables between groups.
Multivariate analysis was performed using stepwise Cox
proportional hazards regression modeling. P values less
than .05 were considered statistically significant and all
P values correspond to two-sided significance tests.
Results
Patient characteristics
There were 95 men and 37 women enrolled in the study.
The median age of subjects was 59 years (39-77). The
median follow up from primary surgery was 54.2 months
(range, 12.1-128.5 months). Primary lesions were found
above 6 cm or more from the anal verge in 82 patients
(62.1%) and below 5 cm in 50 patients (37.9%) (Table 1).
The median interval time between completion of pre-
operative chemoradiation and surgery was 6.2 weeks
(range, 4.4-8.6 weeks). Among the 132 patients, 52
Table 1 Patient characteristics (n = 132)
Variables Number of patients %
Median age 59.0(39-77)
≤ 60 61 46.2







≤ 5.0 112 84.8






















Poorly or mucinous 16 12.1
Body mass index
≤ 22 39 29.5
> 22 93 70.5
*CEA, carcinoembryonic antigen (normal range 0-7 ng/mL).
Numbers in parenthesis indicate ranges.
Table 2 TNM downstaging in a series of 132 rectal cancer
patients treated with preoperative chemoradiotherapy
CR 0 I II III Total
cII* 0 0 1 1 0 2
cIII* 9 2 28 53 38 130
Total 9 2 29 54 38 132
*Clinical stage II or stage III.
Table 3 Correlation of ypT stage and ypN stage (n = 132)
ypT stage ypNx(%) ypN0(%) ypNpos(%) Total
ypTx 3(2.3) 6(4.5) 0(0.0) 9(6.8)
ypT1 0(0.0) 1(0.8) 0(0.0) 1(0.8)
ypT2 4(3.0) 23(17.4) 2(1.5) 29(21.9)
ypT3 4(3.0) 52(39.4) 36(27.3) 92(69.7)
ypT4 0(0.0) 1(0.8) 0(0.0) 1(0.8)
Total 11(8.3) 83(62.9) 38(28.8) 132(100.0)
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out protective ileostomy; 39 (29.5%) underwent ultralow
low anterior resections with or without protective ileos-
tomy; 22 (16.7%) underwent Hartmann’s procedure and
19 patients (14.3%) underwent abdominoperineal resec-
tions. A summary of patient characteristics is shown inTable 1. In this study, 92 patients (69.7%) underwent a
sphincter saving operation without permanent colostomy.
A total of 94 patients (71.2%) were considered as having
node-negative disease, including ypNx and ypN0. In 38
patients (28.8%), the primary tumor was associated with
regional lymph node metastases (ypNpos). The mean
number of retrieved nodes per specimen was 14.2, re-
spectively. The rate of complete sterilization, i.e., staged
ypTxN0 and ypTxNx, was 6.8% (nine patients). Of the 130
patients with clinical stage III, 92 patients (69.7%) (9 + 2 +
28 + 53 patients) were downstaged after chemoradiation
(Table 2). All of the ypNx patients (n = 11) had clinically
significant lymph node enlargement(s).
Lymph node status
Pathologist A evaluated 74 patients and retrieved an
average of 13 (range, 0-24) lymph nodes and Pathologist
B evaluated 58 patients and retrieved 15 (range, 0-31)
lymph nodes, respectively. There were 11 patients (8.3%)
with absence of lymph nodes recovered in the resected
specimen, i.e., ypNx (0 out of 0). The overall pathologic
characteristics of ypT stage and ypN stage are shown in
Table 3. In comparison of patients with ypNx and those
with ypN0, no significant differences were observed in
terms of gender, age, CEA, cell type, and body mass index.
However, significantly lower risk of lymphovascular inva-
sion was observed in the ypNx group, compared with the
ypNpos group (P = 0.001) (Table 4).
Risk factor analyses
In univariate analyses, CEA greater than 5, primary node
status, and lymphovascular invasion had a statistically
significant adverse influence on survival (Table 5). Al-
though the results of multivariate analysis are limited by
the small number of patients, results of stepwise Cox
Table 4 Clinicopathological characteristics of patients according to ypN status (n = 132)
Parameter ypNx,% ypN0,% ypNpos,% P-value P-value, ypNx vs ypN0
Number of patients 11(8.3) 83(62.9) 38(28.8)
Mean age(yr) ± STD 66.9 ± 9.13 59.5 ± 8.80 58.5 ± 11.4 0.434 0.725
Primary tumor location 0.514 0.680
Mid 11(100.0) 70(84.3) 28(73.7)
Lower 0(0.0) 13(15.7) 10(26.3)
Pretreatment CEA(ng/mL) 5.59 ± 5.98 4.02 ± 5.67 7.36 ± 17.73 0.229 0.926
Cell differentiation 0.765 0.443
Well 0(0.0) 7(8.4) 5(13.2)
Moderate 8(72.7) 69(83.1) 27(71.1)
Poorly 3(27.3) 7(8.5) 6(15.7)
Perineural invasion 3(27.3) 3(3.6) 7(18.4) 0.102 0.288
Lymphovascular invasion 3(27.3) 9(10.8) 18(47.4) 0.001 0.435
Body mass index 22.18 ± 1.57 23.39 ± 3.14 22.86 ± 2.61 0.723 0.091
Retrieved nodes - 13.45 ± 7.59 17.9 ± 6.87 0.720 0.047
CEA Carcinoembryonic antigen, STD Standard deviation.
Table 5 Univariate predictors of adverse outcome (n = 132)























Body mass index 0.838
≤ 22 73.4
> 22 77.1
CEA Carcinoembryonic antigen (normal range 0-7 ng/mL), N Number.
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tastasis as a single independent prognostic factor affecting
overall survival (P = 0.029; relative risk, 2.233; 95% Confi-
dence Interval = 1.087-4.587).
Disease recurrence and survival
The overall recurrence rate was 18.3% (25 patients) and
overall cancer-related mortality was 17.4% (23 patients).
No recurrences were observed among the ypNx group.
Comparison of recurrences and cancer-related deaths
showed significant differences between the ypNx and
ypN0 group (P =0.032) (Table 6). Five-year overall sur-
vival for patients with ypNx group 100%. The estimated
five-year overall survival for ypN0 and ypNpos was
84.0% and 60.3%, respectively (Figure 1). The estimated
five-year disease free survival for ypN0 and ypNpos was
82.8% and 58.9%, respectively (Figure 2). No significant
difference in overall survival was observed between the
ypNx and ypN0 group (P = 0.302). However, the ypNpos
group showed significantly worse five-year survival than
the ypNx and ypN0 groups (P = 0.002).
Discussion
Neoadjuvant chemotherapy and radiation therapy for
treatment of locally advanced rectal cancer is a widely
accepted treatment before surgical operation. Although
it was initially used to improve rates of sphincter preser-
vation and to optimize patient tolerance, the ideal num-
ber of nodes for rectal cancer surgery has been an issue
of controversy. Many studies have demonstrated that
the number of lymph nodes involved with a tumor has a
strong impact on outcome for patients treated for rectal
cancer [3]. Indeed, the TNM staging system is based on
whether one to three nodes are involved or four or
Table 6 Recurrence according to ypN status (n = 132)
Parameter ypNx ypN0 ypNpos P-value
Recurrence 0 11 14 0.032
Cancer related mortality 0 10 13 0.002
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trieved nodes in patients with N1 or N2 disease, when
compared to N0 disease, has been reported [3,6]. Al-
though there is no clear agreement on the absolute num-
ber of total retrieved nodes, [3,13-15] the American Joint
Committee on Cancer (AJCC) has recommended at least
12 lymph nodes as the standard for adequate staging of
colon and rectal disease [12,16]. The AJCC staging does
not include an exception criteria for pretreated rectal can-
cer, which in fact may have several factors that interfere
with lymph node retrieval after rectal cancer surgery.
In addition, the impact of absence of lymph nodes in
the resected specimen after radical surgery for treat-
ment of mid to distal rectal cancer after neoadjuvant
chemoradiation has not been clearly defined in terms
of overall survival.
In this study, the mean number of lymph nodes recov-
ered after neoadjuvant chemoradiation followed by radical
surgery was 14.2 LN per specimen, whereas the rate of12 months 36 mo
Number of Patients at Risk
Overall Survival ypNx 11 11
ypN0 81 76
ypNpostive 35 29
Figure 1 Overall survival according to according to ypN status (n = 13ypNx was 7.6%. Findings of this series showed a statisti-
cally significant higher number of nodes in node positive
patients, compared with node negative patients. For ex-
ample, Wong et al. [17] reported that a mean of 14 nodes
was found in node negative patients, as compared with 20
nodes in node positive patients. Unlike the study reported
by Gorog et al. [18] and Kuo et al. [19], in this study, body
surface area did not affect the number of LN retrieved.
The major weakness of this study is that the results are
based on 11 patients with no recurrent disease after ypNx.
The retrospective nature and small sample size might
actually have affected statistical analysis.
In a population-based study, including 5000 patients
with rectal cancer from the SEER (Surveillance, Epidemi-
ology, and End Results) database, results of multivariate
analysis showed that patients who underwent preoperative
radiation had significantly fewer recovered nodes, as com-
pared with patients treated by adjuvant therapy [20]. The
main reason for more retrieved nodes in this study may
have resulted from complete total mesorectal excision
with high ligation of inferior mesenteric vessels; however,
a more likely explanation is the pathologist’s determin-
ation to retrieve as many nodes as possible.
The clinical impact of decreased retrieval of LN after







2) (p = 0.003).
12 months 36 months 60 months 84 months 120 months
Number of Patients at Risk
DFS          ypNx 11 11 11 11 11
ypN0 79 74 67 64 64
ypNpostive 33 28 20 14 14










Figure 2 Disease free survival (DFS) according to ypNx status (n = 132) (p = 0.022).
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number of nodes increases the likelihood of proper staging
and thus might benefit from adjuvant therapy. Is survival
in the ypNx population worse than that in the ypN0 popu-
lation? In our series, the answer is no. The ypNx group
exhibited a tendency toward better overall survival than
the ypN0 group. The ypNx group may reflect an increased
sensitivity to chemoradiation, which ultimately results in
downstaging, as suggested by Habr-Gama et al. [5]. In fact,
some of patients with ypNx could have been node positive
patients before neoadjuvant chemoradiation. The results
of the current series should be interpreted with caution.
Due to the retrospective nature of this study, the analysis
of disease free survival, local recurrence free survival and
overall survival lack significant variables having a major
impact on the outcome. Based on our results, the authors
of this study suggest that the current recommendation of
minimum requirement for LN retrieved (i.e. more than 12
nodes) for proper staging in these subsets of patients may
be inappropriate and that conduct of more larger studies
comparing the therapeutic outcome of ypNx and ypN0 is
definitely warranted.A wide range of tumor responses after preoperative
chemoradiation therapy have been reported [2,6,9,21,22].
The reason for this wide variability in tumor responses is
unclear. The results of studies reporting predictive clinico-
pathologic factors of tumor response are controversial and
patients in the ypNx group may be associated with in-
creased sensitivity toward chemoradiation therapy, and,
thus, toward better survival. Some molecular biomarkers
and various enzymes that may predict tumor response to
chemotherapy have been suggested [19,23-25]. Neoadjuvant
chemoradiation therapy has played a critical role in im-
proving resectability and downstaging tumors. A variety of
neoadjuvant chemoradiation regimens and radiosentisizers
should be investigated for improvement of tumor response
after chemoradiation and further prediction of tumor
response.
In conclusion, absence of recovered LN in a resected
specimen after neoadjuvant chemoradiation is rare and
was observed in 7.6% in this series. Patients with ypNx
after neoadjuvant chemoradiation and radical surgery may
not be considered as patients at high risk for development
of recurrence.
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